Conference Overview - The fifth Synbio China conference will be held in Hangzhou on March 31 to April 1, 2026, at the Hilton Garden Inn [7][9] - The conference aims to gather 1,000 participants and is organized by Synbio Deep Wave and Jiangnan University [7][8] Venue and Accommodation - The main venue is the Hilton Garden Inn, located at 600 Jinsada Avenue, Qiantang District, Hangzhou [6][7] - Accommodation options include: - Hilton Garden Inn: 550 RMB per night including breakfast [6] - Holiday Inn: 238 RMB for a double room, excluding breakfast [6] - City Hotel: 238 RMB for a double room, excluding breakfast [6] Transportation - Transportation options to the venue include: - Taxi from Hangzhou East Station: approximately 25 minutes [4] - Metro from Hangzhou East Station: Line 1 to Jinsahu Station, about 30 minutes [4] - Taxi from Hangzhou Xiaoshan International Airport: approximately 40 minutes [4] Agenda Highlights - The conference will feature various sessions, including: - Day 1 AM: Focus on bio-manufacturing industry ecology and functional food science [10] - Day 1 PM: Specialized sessions on food and skincare [10] - Day 2 AM: Focus on functional ingredients and bio-manufacturing innovation [10] - Day 2 PM: Discussions on future food and all-age nutrition [10] Keynote Speakers - Notable speakers include: - An academic from the German Academy of Engineering discussing low-carbon bio-manufacturing technologies [14] - Experts from Jiangnan University and other institutions presenting on various bio-manufacturing topics [15][19] Industry Collaboration - The conference will facilitate networking and collaboration among industry professionals, researchers, and investors [34] - Opportunities for exhibitors and sponsors to showcase their products and services related to synthetic biology and bio-manufacturing [34]

Core Viewpoint - The company reported a net profit of 32 million yuan for Q3 2025, representing a year-on-year increase of 55.63%, while operating revenue decreased by 15.16% to 903 million yuan, indicating a trend of profit recovery and improved operational quality [5][6][13] Financial Performance - The company achieved a net profit of 0.32 billion yuan in Q3 2025, a 55.63% increase year-on-year [5] - Operating revenue for the same period was 9.03 billion yuan, down 15.16% compared to the previous year [5] - The sales expense ratio decreased to 34.26%, the lowest level in five years, due to optimized brand communication and channel structure [5] - Net cash flow from operating activities increased by 859% year-on-year, indicating significant improvement in core financial metrics [5] Business Strategy - The company is focusing on an integrated business layout from "raw materials to end products," particularly in the field of aging intervention, providing comprehensive solutions across pharmaceuticals, medical aesthetics, nutritional science, and dermatology [6][7] - The core business, which includes raw materials and medical terminal operations, accounts for approximately 60% of total revenue, showing stable development [6] - The company is enhancing its brand communication and market strategies to align with its research attributes, particularly in the skin science innovation sector [6] Asset Impairment - The company recognized credit impairment losses of 17.54 million yuan due to provisions for bad debts and inventory write-downs in Q3 2025 [11][12] - The total provision for bad debts amounted to 14.08 million yuan, representing 20.38% of the accounts receivable balance [12] - The inventory write-down provision was 5.71 million yuan, accounting for 3.56% of the inventory balance [12][13]